(2023) 186:537593.e25
Four Strategic Pathways for Food Marketers As Ozempic, Wegovy, and other GLP-1 medications continue reshaping consumer behaviors, food marketers need a multi-faceted approach to meet these shifting demands
With obesity rates skyrocketing and metabolic dysfunction affecting a vast majority of Americans, these drugs are being hailed as miracle solutions for weight loss and diabetes management
With input from ophthalmologists, diabetologists, and obesity experts across 17 countries in UK & Europe, we explored the evidence around GLP-1 receptor agonists and ocular complications
The secondary objective included efficacy parameters at 24 weeks, assessed by the changes in HbA1c, fasting plasma glucose (FPG), systolic blood pressure (SBP), and body weight at 24 weeks compared to baseline
*Correspondence: Niklas Reich, [email protected] This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers